The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
Viridian Therapeutics, Inc. is down year-to-date despite the company executing its clinical strategy and despite the pipeline advancing in line with the guidance management provided. THRIVE-1 and THRI...
Viridian Therapeutics VRDN has announced detailed plans for a late-stage program on VRDN-003, its investigational subcutaneously (SC)-administered antibody, in patients with moderate-to-severe thyroid...
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseas...
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “company” or “Viridian”), a biopharmaceutical company focused on discovering and developing potential best-in-c...
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare di...
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare di...
Viridian Therapeutics, Inc. (NASDAQ:VRDN ) Q1 2024 Earnings Conference Call May 8, 2024 8:00 AM ET Company Participants Louisa Stone – Manager of Investor Relations Steve Mahoney – President and C...
Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of $1.07. This compares to loss of $1.61 per share a year ago....
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseas...